# Ivantis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ivantis

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.ivantisinc.com
- Total disclosed funding: $132M
- Latest round: Series C (Jan 6, 2017)
- Investors on record: 12

## About

Ivantis, Inc. is a medical technology company specializing in the development of innovative devices for glaucoma treatment, particularly through minimally invasive surgical solutions that enhance patient care.Founded in 2007 and headquartered in Irvine, US, Ivantis, Inc. focuses on developing advanced ophthalmic devices. In January 2022, the company was acquired by Alcon Labs, Inc., enabling it to expand its market reach. The CEO is Dave Van Meter, who has an extensive background in the medical device sector. The company has participated in 10 funding deals, with the latest being a Series C round that raised USD 25.00 mn, leading to a current valuation of USD 177.29 mn.Ivantis, Inc. primarily offers the Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to improve intraocular pressure management in patients with mild to moderate primary open-angle glaucoma. This device creates outflow pathways for aqueous fluid, bypassing the trabecular meshwork to restore natural drainage. The company serves a diverse clientele, including ophthalmic surgeons and surgery centers, with products distributed across North America, Europe, and parts of Asia and South America.Ivantis, Inc. generates revenue through direct sales of its ophthalmic devices and surgical products to healthcare providers and institutions. Its revenue model is B2B, involving partnerships and distribution agreements with hospitals and clinics that perform glaucoma surgeries. Revenue is primarily derived from the sales of proprietary products like the Hydrus® Microstent during cataract procedures, ensuring a broad market presence.The recent acquisition by Alcon Labs, Inc. in January 2022 will facilitate the international launch of the Hydrus Microstent, with plans for ongoing evidence-based research to support product development. The company is expected to focus on expanding into new markets, particularly in Europe and Asia, to reach a broader patient demographic by leveraging its enhanced capabilities post-acquisition.

## Funding rounds

- Series C, Jan 6, 2017, $25M — Delphi Ventures, New Enterprise Associates, GBS Venture Partners, SG Growth Capital, Ascension Ventures, Merieux Equity Partners, MemorialCare Innovation Fund, RA Capital Management, Vertex Ventures HC
- Series B, Sep 23, 2014, $25M — Delphi Ventures, New Enterprise Associates, GBS Venture Partners, SG Growth Capital, Ascension Ventures, Foresite Capital, MemorialCare Innovation Fund, GCI Venture Partners, Vertex Ventures HC
- Series B, Jan 13, 2014, $14M — Delphi Ventures, New Enterprise Associates, GBS Venture Partners, SG Growth Capital, Ascension Ventures, Foresite Capital, Biomedical Sciences Investment Fund, MemorialCare Innovation Fund, GCI Venture Partners, Vertex Ventures HC
- Series B, Aug 20, 2013, $5M — SG Growth Capital
- Series B, Feb 8, 2013, $27M — Delphi Ventures, New Enterprise Associates, Ascension Ventures, MemorialCare Innovation Fund
- Series A, Apr 26, 2011, $17M — Delphi Ventures, New Enterprise Associates
- Series A, Jul 14, 2008, $4.5M — Delphi Ventures, New Enterprise Associates
- Series A, May 12, 2008, $15M — New Enterprise Associates
- Seed, Jun 1, 2007 — New Enterprise Associates

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Seed, Series A, Series B, Series C
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series A, Series B, Series C
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series B, Series C
- MemorialCare Innovation Fund (https://capitalatlas.ai/funds/memorialcare-innovation-fund) — Series B, Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B, Series C
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Biomedical Sciences Investment Fund — Series B
- GCI Venture Partners — Series B
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series B, Series C
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C